Benzinga | Apr 27, 2021 08:03AM EDT

Dynavax Highlights Presentation Of HEPLISAV-B Post-Marketing Observational Study Results At 2021 Annual Conference On Vaccinology Research

Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the results of the post-marketing study assessing the rates of occurrence of acute myocardial infarction (AMI) in persons receiving HEPLISAV-B compared with Engerix-B. The results were selected for an oral presentation at the National Foundation for Infectious Diseases (NFID) 2021 Annual Conference on Vaccinology Research (ACVR), a premier forum for the exchange of scientific and clinical knowledge in vaccinology, being held virtually April 26-27, 2021.